Any notion that sponsor Amylin Pharmaceuticals LLC, a wholly owned subsidiary of Bristol-Myers Squibb Co. (BMS), might receive limited support from the FDA during the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting evaluating its biologics license application (BLA) for metreleptin (recombinant methionyl human leptin) was quashed early Wednesday morning.